Demographic and disease-related characteristics. All data are mean (SD) or n (%).
| Characteristics | Women, n = 71 | Men, n = 16 | Overall, n = 87 |
|---|---|---|---|
| Age, yrs | 28.7 (10.1) | 31.4 (13.8) | 29.2 (10.8) |
| Height, m | 1.6 (0.1) | 1.7 (0.1) | 1.6 (0.9) |
| Weight, kg | 60.2 (16.0) | 67.6 (18.6) | 61.5 (16.7) |
| Body mass index, kg/m2 | 23.4 (5.3) | 24.1 (6.2) | 23.5 (5.5) |
| Disease duration, yrs | 20.6 (11.0) | 24.0 (13.6) | 21.2 (11.5) |
| Current smoker | 16 (22.5) | 2 (22.2) | 18 (22.5) |
| Disease characteristics and treatment | |||
| Disease subtype (ILAR) | |||
| Systemic | 7 (9.9) | 5 (1.3) | 12 (13.8) |
| Oligoarticular | 12 (16.9) | 3 (18.8) | 15 (17.2) |
| Extended oligoarticular | 8 (11.3) | 0 | 8 (9.2) |
| Polyarticular RF-positive | 17 (23.9) | 1 (6.3) | 18 (20.7) |
| Polyarticular RF-negative | 21 (29.6) | 2 (12.5) | 23 (26.4) |
| Psoriasis | 3 (4.2) | 2 (12.5) | 5 (5.8) |
| Enthesitis-related | 2 (2.8) | 2 (12.5) | 4 (4.6) |
| Other | 1 (1.41) | 1 (6.3) | 2 (2.3) |
| RF-positive | 21 (29.6) | 1 (6.3) | 22 (25.3) |
| HAQ score (0–3) | 1.3 (0.8) | 1.5 (0.8) | 1.3 (0.8) |
| ESR, mm/h | 23.2 (20.0) | 21.0 (26.3) | 23.0 (20.5) |
| CRP, mg/l | 17.8 (20.9) | 26.3 (29.2) | 19.2 (22.3) |
| Large-joint arthroplasty (yes vs no) | 16 (22.5) | 4 (66.7) | 20 (26.0) |
| Hip arthroplasty (yes vs no) | 15 (21.1) | 4 (66.7) | 19 (24.7) |
| Knee arthroplasty (yes vs no) | 12 (16.9) | 4 (66.7) | 16 (20.8) |
| Methotrexate (ever, yes vs no) | 20 (29.0) | 2 (25.0) | 22 (28.6) |
| Other DMARD (ever, yes vs no) | 33 (46.5) | 6 (37.5) | 39 (44.8) |
| Oral steroids (ever, yes vs no) | 34 (49.3) | 5 (62.5) | 39 (50.7) |
| Duration of oral steroids, mo | 76.3 (90.1) | 19.0 (24.0) | 72.9 (88.5) |
ILAR: International League of Associations for Rheumatology; RF: rheumatoid factor; HAQ: Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DMARD: disease-modifying antirheumatic drug.